Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa

Sponsor
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
Overall Status
Completed
CT.gov ID
NCT00027183
Collaborator
(none)
134
1
249.4
0.5

Study Details

Study Description

Brief Summary

Some bacteria that cause disease can produce toxic substances that may worsen the disease. Pseudomonas aeruginosa is a bacteria that can produce a variety of toxins and is of special interest for patients with cystic fibrosis and repeated long term lung infections.

The goal of this study is to determine whether specific toxins produced by Pseudomonas aeruginosa may be important in the disease process of chronic lung infections of patients with cystic fibrosis.

This study will attempt to measure bacterial production of toxins in blood and sputum and immune system response to toxins in the blood....

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The goal of this study is to determine whether virulence determinants that use the type III-secretory pathway may be important in the pathogenesis of chronic Pseudomonas aeruginosa lung infections in patients with cystic fibrosis (CF). The studies will quantify bacterial effector proteins in serum and sputum and the immune response to specific products as reflected by antibodies in serum. Candidate effector proteins include: (1) exotoxin A, a non-type III-dependent ADP-ribosyltransferase and cytotoxin that does not use the Type III secretory pathway, (2) ExoS, a type III pathway-dependent extracellular ADP-ribosyltransferase with cytotoxic activity, (3) ExoU, another type III-dependent cytotoxin, that is responsible for epithelial injury in acute lung infections, and (4) PcrV, a homolog to the V antigen of Yersinia.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    134 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Role of Exotoxins in the Pathogenesis of Pseudomonas Aeruginosa
    Actual Study Start Date :
    Mar 17, 1998
    Actual Primary Completion Date :
    Sep 7, 2006
    Actual Study Completion Date :
    Dec 28, 2018

    Arms and Interventions

    Arm Intervention/Treatment
    1

    Healthy Volunteers

    2

    Cystic Fibrosis subjects

    Outcome Measures

    Primary Outcome Measures

    1. Serum will be analyzed for the presence of an immune response, focusing on antibodies against the virulence determinants, whilesputum will be analyzed for the immunological and genetic presence of the virulence determinants. [End of Study]

      serum will be analyzed for the presence of an immune response, focusing on antibodies against the virulence determinants, whilesputum will be analyzed for the immunological and genetic presence of the virulence determinants.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    9 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    • INCLUSION CRITERIA:

    Patients with cystic fibrosis with a defined mutation in the cystic fibrosis transmembrane regulator (CFTR) (e.g., any of the known variants of the CFTR gene, such as the delta F508 allele).

    Patients will have been tested or will be tested for the CFTR gene under another protocol.

    Research volunteers that are age-and race-matched as control subjects.

    EXCLUSION CRITERIA:

    Patients who are less than 9 years of age. Research volunteers less than 18 years of age.

    Patients or research volunteers who test positive for human immunodeficiency virus (HIV) or a positive serum test for hepatitis B and/or C virus.

    Patients or research volunteers who test positive for tuberculosis.

    Research volunteers with pulmonary disease or infection.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland United States 20892

    Sponsors and Collaborators

    • National Heart, Lung, and Blood Institute (NHLBI)

    Investigators

    • Principal Investigator: Joel Moss, M.D., National Heart, Lung, and Blood Institute (NHLBI)

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    National Heart, Lung, and Blood Institute (NHLBI)
    ClinicalTrials.gov Identifier:
    NCT00027183
    Other Study ID Numbers:
    • 980062
    • 98-H-0062
    First Posted:
    Nov 28, 2001
    Last Update Posted:
    Jun 6, 2022
    Last Verified:
    Jun 1, 2022
    Keywords provided by National Heart, Lung, and Blood Institute (NHLBI)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 6, 2022